ArticlePathogens (Basel, Switzerland)2026
Performance of High-Resolution Melting Analysis for Molecular Detection and Species Differentiation of Malaria: A Scoping Review.
Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malaria diagnosis remains challenging in low-density, asymptomatic, mixed-species, and non-falciparum infections. This scoping review mapped the diagnostic and operational evidence for high-resolution melting (HRM) analysis in malaria. Following PRISMA-ScR guidance, PubMed and Scopus were searched for English-language studies published between 2016 and 2026. Two reviewers independently screened records in Rayyan. Of 162 records identified, 15 studies met the eligibility criteria. Most assays targeted 18S rRNA, although mitochondrial, apicoplast, species-specific, and resistance-associated markers were also evaluated. Reported sensitivity ranged from 91.76% to 100%, and specificity generally exceeded 92%. HRM enabled differentiation of major human-infecting
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.